Pricing

Atea Pharmaceuticals Inc. (AVIR)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Jean-Pierre Sommadossi
Employees:
70
225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
857-204-8109

Are you looking for this stock instead?

Atea Pharmaceuticals, Inc. focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor, and AT-281, a pharmaceutically acceptable salt.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available